1.	Phase III Randomized Study of Liarozole Fumarate (R85246) vs PRED for Metastatic, Hormone-Refractory Prostate Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Protocol IDs: YALE-HIC-7586, NCI-V95-0727
2.	Phase II Study of Liarozole Fumarate for Unresectable or Metastatic Breast Cancer (Summary Last Modified 07/98) Phase: Phase II Type: Treatment Status: Closed Age: postmenopausal Sponsor: Protocol IDs: EORTC-10941
3.	Phase II Pilot Study of Liarozole in Myelodysplastic Syndrome (Summary Last Modified 06/97) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: JRF-LIA-USA-31, NCI-V95-0745
4.	Phase II Pilot Study of Liarozole in Progressive or Recurrent Squamous Cell Carcinoma of the Cervix (Summary Last Modified 06/97) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: JRF-LIA-USA-25, NCI-V95-0746
5.	Phase II Pilot Study of Liarozole Fumarate for Recurrent non-Small Cell Lung Cancer (Summary Last Modified 08/96) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: YALE-HIC-8592, NCI-V96-0889
6.	Phase II Randomized, Double-Blind Study of 3 Doses of Liarozole Fumarate in Patients with Rising PSA Levels After Definitive Local Treatment for Stage I/II/III Prostate Cancer (Summary Last Modified 02/98) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: JRF-LIA-INT-26, NCI-V97-1121
7.	Phase II Multicenter Study of R-75251 in Patients with Progressive, Measurable, Metastatic Prostate Cancer (Summary Last Modified 12/91) Phase: Phase II Type: Treatment Status: Closed Age: any age Sponsor: Protocol IDs: EORTC-30902